IGKC and FcγR genotypes and humoral immunity to HER2 in breast cancer

Immunobiology

Volumn 219, Issue 2, 2014, Pages 113-117

  Pandey, Janardan P ^a   Kistner Griffin, Emily ^a   Black, Laurel ^a   Namboodiri, Aryan M ^a   Iwasaki, Motoki ^b   Kasuga, Yoshio ^c   Hamada, Gerson S ^d   Tsugane, Shoichiro ^b  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b NATIONAL CANCER CENTER   (Japan)

^c Nagano Matsushiro General Hospital   (Japan)

^d Nikkei Disease Prevention Center   (Brazil)

Author keywords

Antibody response; Fc R; GM; HER2; IGKC; KM

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 2 ANTIBODY; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; FC RECEPTOR; FC RECEPTOR IIA; FC RECEPTOR IIIA; UNCLASSIFIED DRUG;

ALLELE; ALLOTYPE; ANTIBODY RESPONSE; ARTICLE; BREAST CANCER; CANCER IMMUNOLOGY; CANCER PROGNOSIS; CANCER RISK; CANCER SUSCEPTIBILITY; CASE CONTROL STUDY; CONTROLLED STUDY; EPISTASIS; FC GAMMA R GENE; FC GAMMA RIIA GENE; FC GAMMA RIIIA GENE; FEMALE; GENE FREQUENCY; GENE LINKAGE DISEQUILIBRIUM; GENE LOCUS; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOTE; HISPANIC; HOMOZYGOTE; HUMAN; HUMORAL IMMUNITY; IMMUNOGLOBULIN GENE; IMMUNOGLOBULIN KAPPA CONSTANT GENE; JAPANESE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RACE DIFFERENCE; RECEPTOR GENE;

ANTIBODY RESPONSE; FCΓR; GM; HER2; IGKC; KM;

ALLELES; ANTIGENS, NEOPLASM; BRAZIL; BREAST NEOPLASMS; CARCINOMA; CASE-CONTROL STUDIES; FEMALE; FOLLOW-UP STUDIES; GENETIC ASSOCIATION STUDIES; GENOTYPE; HUMANS; IMMUNITY, HUMORAL; IMMUNOGLOBULIN KAPPA-CHAINS; JAPAN; LINKAGE DISEQUILIBRIUM; POLYMORPHISM, GENETIC; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, IGG; RISK FACTORS;

EID: 84891824350     PISSN: 01712985     EISSN: 18783279     Source Type: Journal    
DOI: 10.1016/j.imbio.2013.08.005     Document Type: Article

References (17)

1. Antonsson A., Bialasiewicz S., Rockett R.J., Jacob K., Bennett I.C., Sloots T.P. Exploring the prevalence of ten polyomaviruses and two herpes viruses in breast cancer. PLoS ONE 2012, 7:e39842.
2. Biggar R.J., Pandey J.P., Henle W., Nkrumah F.K., Levine P.H. Humoral immune response to Epstein-Barr virus antigens and immunoglobulin allotypes in African Burkitt lymphoma patients. Int. J. Cancer 1984, 33:577-580.
3. Casadevall A., Pirofski L.A. A new synthesis for antibody-mediated immunity. Nat. Immunol. 2012, 13:21-28.
4. Dhodapkar K.M., Krasovsky J., Williamson B., Dhodapkar M.V. Antitumor monoclonal antibodies enhance cross-presentation of cellular antigens and the generation of myeloma-specific killer T cells by dendritic cells. J. Exp. Med. 2002, 195:125-133.
5. Iwasaki M., Shimada N., Kasuga Y., Yokoyama S., Onuma H., Nishimura H., et al. Fragment c gamma receptor gene polymorphisms and breast cancer risk in case-control studies in Japanese, Japanese Brazilians, and non-Japanese Brazilians. Breast Cancer Res. Treat. 2011, 126:497-505.
6. Joshi D., Buehring G.C. Are viruses associated with human breast cancer? Scrutinizing the molecular evidence. Breast Cancer Res. Treat. 2012, 135:1-15.
7. Lefranc M.P., Lefranc G. Human Gm, Km, and Am allotypes and their molecular characterization: a remarkable demonstration of polymorphism. Methods Mol. Biol. 2012, 882:635-680.
8. Lehner B. Molecular mechanisms of epistasis within and between genes. Trends Genet. 2011, 27:323-331.
9. Moore J.H. The ubiquitous nature of epistasis in determining susceptibility to common human diseases. Hum. Hered. 2003, 56:73-82.
10. Moxley G.M., Gibbs R.S. Polymerase chain reaction-based genotyping for allotypic markers of immunoglobulin kappa shows allelic association of Km with kappa variable segment. Genomics 1992, 13:104-108.
11. Pandey J.P., Li Z. The forgotten tale of immunoglobulin allotypes in cancer risk and treatment. Exp. Hematol. Oncol. 2013, 2:6.
12. Pandey J.P., Namboodiri A.M., Kistner-Griffin E., Iwasaki M., Kasuga Y., Hamada G.S., Tsugane S. Racially restricted contribution of immunoglobulin Fcγ and Fcγ receptor genotypes to humoral immunity to human epidermal growth factor receptor 2 in breast cancer. Clin. Exp. Immunol. 2013, 171:273-277.
13. Rafiq K., Bergtold A., Clynes R. Immune complex-mediated antigen presentation induces tumor immunity. J. Clin. Invest. 2002, 110:71-79.
14. Schmidt M., Hellwig B., Hammad S., Othman A., Lohr M., Chen Z., et al. A comprehensive analysis of human gene expression profiles identifies stromal immunoglobulin kappa C as a compatible prognostic marker in human solid tumors. Clin. Cancer Res. 2012, 18:2695-2704.
15. Schmidt M., Hengstler J.G., von Törne C., Koelbl H., Gehrmann M.C. Coordinates in the universe of node-negative breast cancer revisited. Cancer. Res. 2009, 69:2695-2698.
16. Taylor C., Hershman D., Shah N., Suciu-Foca N., Petrylak D.P., Taub R., Vahdat L., Cheng B., Pegram M., Knutson K.L., Clynes R. Augmented HER-2 specific immunity during treatment with trastuzumab and chemotherapy. Clin. Cancer Res. 2007, 13:5133-5143.
17. Torres M., Fernandez-Fuentes N., Fiser A., Casadevall A. The immunoglobulin heavy chain constant region affects kinetic and thermodynamic parameters of antibody variable region interactions with antigen. J. Biol. Chem. 2007, 282:13917-13927.